Eighty Percent of Companies Without Electronic Patient Recorded Outcome Systems Plan to Introduce the Technology Within Three Years

RESEARCH TRIANGLE PARK, NC --(Marketwired - March 01, 2016) - In addition to improving data quality and reliability, transitioning from a paper-and-pen patient-reported outcome (PRO) approach to an electronic system also shortens study timelines and helps to ensure that a PRO-driven endpoint makes it to the final product label. As such, 80 percent of surveyed companies without electronic PRO (ePRO) technology plan to implement it within three years, according to primary intelligence provider Cutting Edge Information.

Efficient data collection is key to ensuring data quality and ultimately to supporting labelling claims. However, compared to standard clinical trial data, PROs are self-reported and, therefore, more unreliable. Adopting ePRO delivery mechanisms helps to improve data quality.

"Electronic data capture allows for real-time PRO data collection from patients completing questionnaires both on- and off-site," says Victoria Cavicchi senior research analyst at Cutting Edge Information. "Data quality is improved, as it is less likely that patients will skip a question or answer incorrectly in an electronic format."

Of the 80 percent of companies that intend to implement ePRO technology within three years, 20 percent will do so in the next year. And, although teams can show a clear benefit from ePRO, the initial cost of these modalities can be daunting compared to more traditional methods. Twenty percent of companies without an ePRO strategy have no plans to implement this technology.

A recent study by Cutting Edge Information, Patient-Reported Outcomes: Infusing the Healthcare Consumer Voice into Clinical Development and Reimbursement, found at http://www.cuttingedgeinfo.com/research/market-access/patient-reported-outcomes/, provides insights and metrics, collected through primary research that life sciences executives can leverage to:

• Add PRO endpoints and measurements into clinical trials to add value to drug dossiers/payer discussions.
• Develop and standardize in-house PRO development and implementation practices.
• Determine best-fit PRO measurements as well as decide how many to use and how to leverage them in regulatory and reimbursement discussions.
• Examine PROs' ability to achieve key study goals in four therapeutic areas: CNS, respiratory, immunology and oncology.
• Understand emerging topics and trends in the PRO space, including the rise of ePRO technology and its impact on data quality.

Image Available: http://www.marketwire.com/library/MwGo/2016/3/1/11G085305/Images/February_2016_PH203_4.6-e659724777e49499917c81f4f8b5fa63.jpg